CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?

Area of Science:

• Oncology
• Cardiology
• Immunotherapy

Background:

• CD19-specific chimeric antigen receptor (CAR) T cell therapy offers a promising treatment for refractory hematological malignancies.
• Significant toxicities, including cytokine release syndrome and neurotoxicity, are known complications.
• Cardiovascular toxicity associated with CAR T cell therapy is not well-characterized.

Purpose of the Study:

• To review the current understanding of cardiovascular toxicities linked to CD19-specific CAR T cell therapies.
• To propose a cardiac surveillance protocol for patients undergoing this treatment.
• To outline future research directions in cardio-oncology for CAR T cell therapy.

Main Methods:

• Literature review of reported cardiovascular adverse events.
• Analysis of existing data on CAR T cell therapy-related cardiac complications.
• Synthesis of current knowledge and expert opinion.

Main Results:

• Observed cardiovascular adverse effects include sinus tachycardia, arrhythmias, left ventricular systolic dysfunction, hypotension, and shock.
• The existing literature on CAR T cell therapy-induced cardiovascular toxicity is limited.
• Prospective studies are needed to fully define cardiac safety.

Conclusions:

• CD19-specific CAR T cell therapy, while effective, carries risks of significant cardiovascular toxicity.
• A structured cardiac surveillance protocol is proposed to monitor patients.
• Further research is essential to optimize the cardiac safety and efficacy of CAR T cell therapies.